Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Benign prostatic hyperplasia: treatment in primary care.

Literature DB >> 16960209

Benign prostatic hyperplasia: treatment in primary care.

Anand K Patel¹, Christopher R Chapple.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2006 PMID： 16960209 PMCID： PMC1562476 DOI： 10.1136/bmj.38946.616551.BE1

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

18 in total

1. Guideline for the primary care management of male lower urinary tract symptoms.

Authors: M J Speakman; R S Kirby; A Joyce; P Abrams; R Pocock
Journal: BJU Int Date: 2004-05 Impact factor: 5.588

2. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.

Authors: P van Kerrebroec; A Jardin; P van Cangh; K U Laval
Journal: Eur Urol Date: 2002-01 Impact factor: 20.096

3. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group.

Authors: S Kaplan; D Garvin; P Gilhooly; M Koppel; R Labasky; R Milsten; P Reddy; S Rosenberg; D Sussman; C White; M Lee; F Pappas; J Waldstreicher
Journal: Urology Date: 2000-10-01 Impact factor: 2.649

4. Intraoperative floppy iris syndrome associated with tamsulosin.

Authors: David F Chang; John R Campbell
Journal: J Cataract Refract Surg Date: 2005-04 Impact factor: 3.351

5. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

Authors: John D McConnell; Claus G Roehrborn; Oliver M Bautista; Gerald L Andriole; Christopher M Dixon; John W Kusek; Herbert Lepor; Kevin T McVary; Leroy M Nyberg; Harry S Clarke; E David Crawford; Ananias Diokno; John P Foley; Harris E Foster; Stephen C Jacobs; Steven A Kaplan; Karl J Kreder; Michael M Lieber; M Scott Lucia; Gary J Miller; Mani Menon; Douglas F Milam; Joe W Ramsdell; Noah S Schenkman; Kevin M Slawin; Joseph A Smith
Journal: N Engl J Med Date: 2003-12-18 Impact factor: 91.245

Review 6. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.

Authors: Christopher R Chapple
Journal: BJU Int Date: 2004-09 Impact factor: 5.588

7. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.

Authors: Claus G Roehrborn; Leonard S Marks; Tom Fenter; Sheldon Freedman; John Tuttle; Marc Gittleman; Betsy Morrill; Eric T Wolford
Journal: Urology Date: 2004-04 Impact factor: 2.649

8. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines).

Authors: Stephan Madersbacher; Gerasimos Alivizatos; Jorgen Nordling; Carlos Rioja Sanz; Mark Emberton; Jean J M C H de la Rosette
Journal: Eur Urol Date: 2004-11 Impact factor: 20.096

Review 9. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia.

Authors: Gerald L Andriole; Roger Kirby
Journal: Eur Urol Date: 2003-07 Impact factor: 20.096

Review 10. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials.

Authors: Jayne E Edwards; R Andrew Moore
Journal: BMC Urol Date: 2002-12-12 Impact factor: 2.264

3 in total